Abdel-Aziz Mohamed M, Lotfy Mahmoud, El-Kady Ibrahim M, Abozaid Mostafa
Biotechnology Research Laboratories Division, Gastro-Entrology Surgery Center, Mansoura University, Mansoura, Egypt.
Cancer Detect Prev. 2009;32(4):329-35. doi: 10.1016/j.cdp.2005.10.006. Epub 2006 May 2.
Enzyme-linked immunosorbent assay (ELISA) was used for analysis of serum mutant p53 protein, carcinoembryonic antigen (CEA), and epidermal growth factor receptor (EGFR). Serum samples were obtained from 48 patients with colorectal cancer (CRC) and a control group of twenty healthy individuals.
The results demonstrated a significant increase of serum mutant p53, EGFR, and CEA levels in CRC patients compared to the control group (P<0.001 for each). Mutant p53 protein was significantly different in the different CRC grades (P=0.028). p53, CEA, and EGFR can differentiate successfully between different CRC grades and normal control (P<0.001 for each). Sensitivities of p53, CEA, and EGFR were 39.6, 31, and 71%, respectively. There was no correlation between CEA, EGFR, and p53 indicating that these variables were independent. Positive status of serum CEA and (or) p53 was found in 29 out of 48 (60%) patients. Also, positive status of serum CEA and (or) EGFR was found in 39 out of 48 (81%) patients.
Thus, the simultaneous determination of p53 or EGFR combined with the CEA may increase the sensitivity to diagnose CRC patients and may aid in disease prognosis.
采用酶联免疫吸附测定法（ELISA）分析血清突变型p53蛋白、癌胚抗原（CEA）和表皮生长因子受体（EGFR）。从48例结直肠癌（CRC）患者和20名健康个体组成的对照组中获取血清样本。
结果显示，与对照组相比，CRC患者血清中突变型p53、EGFR和CEA水平显著升高（每项P<0.001）。不同CRC分级中突变型p53蛋白存在显著差异（P=0.028）。p53、CEA和EGFR能够成功区分不同的CRC分级与正常对照组（每项P<0.001）。p53、CEA和EGFR的敏感性分别为39.6%、31%和71%。CEA、EGFR和p53之间无相关性，表明这些变量相互独立。48例患者中有29例（60%）血清CEA和（或）p53呈阳性。此外，48例患者中有39例（81%）血清CEA和（或）EGFR呈阳性。
因此，同时检测p53或EGFR并结合CEA可能会提高诊断CRC患者的敏感性，并有助于疾病预后判断。
